Company intelligence / Profile preview

NEX

Seoul, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

NEX-I is a South Korean biotechnology company founded in 2021 that specializes in the development of next-generation immunotherapeutics for cancer. The company utilizes its proprietary ONCOKINE platform to identify novel factors in the tumor microenvironment that contribute to immune resistance and refractory cancer phenotypes. Its lead candidate, NXI-101, is an antibody targeting ONCOKINE-1, which has been licensed to Ono Pharmaceutical for global development. NEX-I aims to overcome the limitations of existing immunotherapies by targeting these newly discovered resistance factors to improve patient response rates and clinical outcomes.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Partnerships

Ono PharmaceuticalGC BiopharmaXsphera BiosciencesDaewoong Pharmaceutical

Beyond the preview

Go deeper on NEX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEX.

Explore the full profile